NASDAQ · COSM
Healthcare · Drug Manufacturers - Specialty & Generic
$0.30
Down-$0.00 (-1.55%)
Updated Nov 4, 2026, 6:21 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · COSM
1M range · 0 trading sessions · Daily adjusted prices
COSM does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning COSM.
Company
Market Activity
Research & News
COSM research
Company profile and research snapshot.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 20, 2026
Initial purchase order of 126,000 Sky Premium Life units secured on execution of the agreementExclusive rights across Saudi Arabia for an initial five years, spanning pharmacies, retail and online platforms, with
Benzinga · Aug 19, 2026
Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.01 by 1100 percent. This is unchanged from the same period last year. The company reported
Benzinga · Mar 10, 2026
Cosmos Health Inc.
Yahoo · Feb 24, 2026
CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company’s biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COSM.
